Mylan Prepares To Launch Insulin Glargine After Another Lantus IP Win

IPR Victory In US Follows Favorable District Court Ruling In March

Lantus_Glargine
Mylan is ready to launch a US Lantus rival upon FDA approval • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin